Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefacetrile is a broad-spectrum first-generation cephalosporin antibiotic derived from 7-aminocephalosporanic acid. It is effective against many Gram-positive and some Gram-negative bacterial infections. Cefacetrile acts by binding to and inactivating penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall, thereby inhibiting the final stages of bacterial cell wall synthesis. This leads to cell lysis mediated by autolytic enzymes such as autolysins. It is used both in human medicine and veterinary applications (notably for mastitis in lactating cows). The drug achieves high serum levels after administration and is rapidly excreted via urine[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefacetrile.